Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539804 | 0.89 | KDM4E (0.58) | DRD2SIGMAR1KDM4EGAAKCNH2 | |
| SCHEMBL5542026 | 0.88 | KDM4E (0.65) | DRD2SIGMAR1KDM4EGAAKCNH2 | |
| SCHEMBL5542882 | 0.86 | KDM4E (0.68) | DRD2SIGMAR1KDM4EGAAKCNH2 | |
| SCHEMBL188197 | 0.85 | CHRNA7 (0.66) | DRD2SIGMAR1KDM4EGAACHRNA7 | |
| SCHEMBL4576516 | 0.82 | DRD2 (0.46) | DRD2SIGMAR1KDM4EGAACHRNA7 | |
| SCHEMBL188554 | 0.81 | KCNH2 (0.46) | DRD2SIGMAR1KDM4EKCNH2DRD3 | |
| SCHEMBL3453669 | 0.81 | DRD2 (1.00) | DRD2SIGMAR1CHRNA7KCNH2DRD3 | |
| SCHEMBL1814737 | 0.81 | DRD2 (0.47) | DRD2SIGMAR1CHRNA7KCNH2DRD3 | |
| SCHEMBL27581509 | 0.80 | DRD2 (0.65) | DRD2SIGMAR1KDM4EGAACHRNA7 | |
| SCHEMBL5795262 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961743-B1 | 1-SUBSTITUTED, 4-(SUBSTITUTED PHENOXYMETHYL)-1,2,3-TRIAZOLE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND METHODS FOR PREPARATION THEREOF | FDC LTD (IN) | 2018-06-20 | — | — | EP | disclosed |
| US-20160009692-A1 | 1-SUBSTITUTED, 4-(SUBSTITUTED PHENOXYMETHYL)-1,2,3-TRIAZOLE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND METHODS FOR PREPARATION THEREOF | FDC LIMITED (IN) | 2016-01-14 | — | — | US | disclosed |
| EP-2961743-A1 | 1-SUBSTITUTED, 4-(SUBSTITUTED PHENOXYMETHYL)-1,2,3-TRIAZOLE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND METHODS FOR PREPARATION THEREOF | FDC Limited (IN) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014132267-A1 | 1-SUBSTITUTED, 4-(SUBSTITUTED PHENOXYMETHYL)-1,2,3-TRIAZOLE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND METHODS FOR PREPARATION THEREOF | FDC LIMITED (IN) | 2014-09-04 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20080219996-A1 | Molecular Markers Associated with Bone Metastasis | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| EP-1931994-A2 | MOLECULAR MARKERS ASSOCIATED WITH BONE METASTASIS | Novartis AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | MISSBACH MARTIN | 2007-06-14 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1651238-A1 | COMBINATIONS OF A CATHEPSIN K INHIBITOR AND A BISPHOPHONATE IN THE TREATMENT OF BONE METASTASIS, TUMOR GROWTH AND TUMOR-INDUCED BONE LOSS | Novartis AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | ALTMANN EVA | 2006-04-06 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005049028-A1 | USE OF CATHEPSIN K INHIBITORS IN SEVERE BONE LOSS DISEASES | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005014006-A1 | COMBINATIONS OF A CATHEPSIN K INHIBITOR AND A BISPHOPHONATE IN THE TREATMENT OF BONE METASTASIS, TUMOR GROWTH AND TUMOR-INDUCED BONE LOSS | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1423121-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | CTSK, CTSB, CTSZ | DRD2 4681/4885SIGMAR1 4880/4885KDM4E 1710/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | DRD2 542/4885SIGMAR1 234/4885KDM4E 4854/4885 |
| US-20160009692-A1 | 1-SUBSTITUTED, 4-(SUBSTITUTED PHENOXYMETHYL)-1,2,3-TRIAZOLE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND METHODS FOR PREPARATION THEREOF | ERG28, CYP51A1, CYP2E1 | DRD2 2750/4885SIGMAR1 1187/4885KDM4E 1698/4885 |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | DRD2 4763/4885SIGMAR1 4150/4885KDM4E 1219/4885 |
| US-20080219996-A1 | Molecular Markers Associated with Bone Metastasis | BST2, BSG, CD44 | DRD2 4666/4885SIGMAR1 2689/4885KDM4E 4385/4885 |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | DRD2 4752/4885SIGMAR1 4489/4885KDM4E 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.